Elevated serum sCD23 and sCD30 up to two decades prior to diagnosis associated with increased risk of non-Hodgkin lymphoma.

The article presents a study that determines the influence of immune markers soluble such as sCD23 and sCD30 on the risk factors for non-Hodgkin lymphoma (NHL). Overview of the background of the study which observes 272 patients with NHL cases is discussed. Information on the findings of the study which suggests the possibility of serums, sCD23 and sCD30, as B-cell-stimulative risk factor for NHL is offered.